Cargando…

Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2

PURPOSE: STAT2 is both an effector and negative regulator of type I interferon (IFN-I) signalling. We describe the characterization of a novel homozygous missense STAT2 substitution in a patient with a type I interferonopathy. METHODS: Whole-genome sequencing (WGS) was used to identify the genetic b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Gaofeng, Badonyi, Mihaly, Franklin, Lina, Seabra, Luis, Rice, Gillian I., Anne-Boland-Auge, Deleuze, Jean-François, El-Chehadeh, Salima, Anheim, Mathieu, de Saint-Martin, Anne, Pellegrini, Sandra, Marsh, Joseph A., Crow, Yanick J., El-Daher, Marie-Therese
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110676/ https://www.ncbi.nlm.nih.gov/pubmed/36753016 http://dx.doi.org/10.1007/s10875-023-01445-3

Ejemplares similares

The type I interferonopathies: 10 years on
por: Crow, Yanick J., et al.
Publicado: (2021)

Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview
por: Rodero, Mathieu P., et al.
Publicado: (2016)

Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype
por: Clarke, S. L. N., et al.
Publicado: (2020)

Monogenic interferonopathy presenting as CMV infection in infancy
por: Schütz, C, et al.
Publicado: (2015)

Large protein complex interfaces have evolved to promote cotranslational assembly
por: Badonyi, Mihaly, et al.
Publicado: (2022)

Buffering of genetic dominance by allele-specific protein complex assembly
por: Badonyi, Mihaly, et al.
Publicado: (2023)

Identification of type I interferonopathies using blood interferon signature: the experience of a pediatric rheumatology center
por: Volpi, S, et al.
Publicado: (2015)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Lung involvement in monogenic interferonopathies
por: Cazzato, Salvatore, et al.
Publicado: (2020)

Type I Interferonopathies in Childhood
por: Haşlak, Fatih, et al.
Publicado: (2023)

Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy
por: Gruber, Conor, et al.
Publicado: (2020)

Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report
por: Schnappauf, Oskar, et al.
Publicado: (2021)

Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome
por: Meuwissen, Marije E.C., et al.
Publicado: (2016)

Type I interferonopathies in pediatric rheumatology
por: Volpi, Stefano, et al.
Publicado: (2016)

Type I Interferonopathies in Children: An Overview
por: d'Angelo, Debora M., et al.
Publicado: (2021)

Comment on: homozygous variant p. Arg90His in NCF1 is associated with early-onset interferonopathy: a case report
por: Goulielmos, George N., et al.
Publicado: (2021)

Mosaic tetrasomy 9p: a mendelian interferonopathy associated with pediatric-onset overlap myositis
por: Frémond, M-L, et al.
Publicado: (2015)

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018)

Covid-19–Associated Myopathy Caused by Type I Interferonopathy
por: Manzano, Giovanna S., et al.
Publicado: (2020)

ZBP1 contributes to interferonopathies caused by impaired ADAR1 function
por: Fang, Xiuwu, et al.
Publicado: (2022)

Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
por: Galbraith, Matthew D., et al.
Publicado: (2023)

Human RELA dominant-negative mutations underlie type I interferonopathy with autoinflammation and autoimmunity
por: Moriya, Kunihiko, et al.
Publicado: (2023)

Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies
por: Kim, Hanna, et al.
Publicado: (2020)

Interferonopathies masquerading as non-Mendelian autoimmune diseases: pattern recognition for early diagnosis
por: Gagne, Samuel, et al.
Publicado: (2023)

Familial Blau syndrome: First molecularly confirmed report from India
por: Janarthanan, Mahesh, et al.
Publicado: (2019)

HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies
por: Marié, Isabelle J., et al.
Publicado: (2018)

Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
por: Dell’Isola, Giovanni Battista, et al.
Publicado: (2023)

Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy
por: Meesilpavikkai, Kornvalee, et al.
Publicado: (2019)

Fine-tuning of type I IFN-signaling in microglia — implications for homeostasis, CNS autoimmunity and interferonopathies
por: Goldmann, Tobias, et al.
Publicado: (2016)

Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response
por: Du, Hekang, et al.
Publicado: (2023)

Dirty Fish Versus Squeaky Clean Mice: Dissecting Interspecies Differences Between Animal Models of Interferonopathy
por: Rutherford, Holly A., et al.
Publicado: (2021)

Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)
por: Kanazawa, Nobuo, et al.
Publicado: (2023)

Clinical non-penetrance associated with biallelic mutations in the RNase H2 complex
por: Crow, Yanick J
Publicado: (2023)

Type 1 Diabetes and Type 1 Interferonopathies: Localization of a Type 1 Common Thread of Virus Infection in the Pancreas
por: Jean-Baptiste, Virginie S.E., et al.
Publicado: (2017)

Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib
por: Zhang, Shiyu, et al.
Publicado: (2021)

Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy
por: Duncan, Christopher James Arthur, et al.
Publicado: (2021)

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China
por: Li, Wendao, et al.
Publicado: (2022)

SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells
por: Descours, Benjamin, et al.
Publicado: (2012)

A homozygous MED11 C-terminal variant causes a lethal neurodegenerative disease
por: Calì, Elisa, et al.
Publicado: (2022)

The SKIV2L RNA exosome limits activation of the RIG-I-like receptors
por: Eckard, Sterling C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2jn7sisid7c28co8sii28ebdgq